Zenex Animal Health makes strategic European play with VievePharm acquisition

VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets

Novartis completes $12 billion acquisition of Avidity Biosciences

The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity

Synthekine teams up with Merck to test breakthrough lung cancer combo

The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases

CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC

Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity

Starton Therapeutics doses first patient in Phase 2a trial of STAR-LLD for multiple myeloma

The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.

Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies

Under the deal, Quiver will receive an undisclosed advance payment and research support

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies

BioVersys’ novel TB drug shows promising results in Phase 2a Trial

The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project

BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal